mass spectrometry comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-08-11. Numbers and descriptions here follow the published literature rather than marketing material.
BPC-157 is a synthetic pentadecapeptide with the sequence GEPPPGKPADDAGLV, corresponding to a partial fragment of a larger protein detected in human gastric juice. The name derives from the parent protein designation BPC, an abbreviation of body protection compound, with 157 acting as a fraction or batch identifier used by the original investigators. Its molecular weight is approximately 1419 daltons, and the chain contains no unusual residues or disulfide bridges. In the literature it is described as a short, water-soluble fragment rather than a complete natural protein.
Most early work on this peptide originated in the 1990s from a research group in Zagreb, Croatia, relying on animal models and cell cultures. Reported observations included effects on gastrointestinal lesion healing, tendon fibroblast migration, and blood vessel formation under controlled laboratory conditions. These findings come predominantly from rodent studies and in vitro assays rather than from human trials. Controlled human data remain limited, and the degree to which animal results translate to human physiology is an open question rather than a settled fact.
Doses in the literature are usually expressed in micrograms or nanograms per kilogram of body weight. Investigators have administered the peptide by several routes, including injection and oral delivery, depending on the question asked. Route and dose vary widely across studies, which complicates direct comparison of results. Many papers report effects at low doses, but the absence of a standardized protocol limits generalization. Reporting practice differs between research groups.
Some properties, such as the peptide's sequence and molecular mass, are firmly established. Other claims, particularly about mechanism and clinical benefit, remain open questions. Proposed mechanisms include effects on nitric oxide signaling and on cell migration, but these are hypotheses supported by limited evidence. Reviewers often note that the field lacks large controlled human trials. Positive animal findings are best treated as signals for further study rather than as settled conclusions.
Most published studies examine BPC-157 in animal models rather than in humans. Common subjects include rats and mice, and researchers often use models of tissue injury, surgery, or induced inflammation. Reported endpoints include healing rates, blood vessel formation, and markers of tissue repair. These designs provide controlled comparisons, but findings in animals do not automatically transfer to people. Human clinical data remain limited and are frequently described as preliminary.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C62H98N16O22 | computed for the free peptide |
| Molecular weight | about 1419 Da | monoisotopic mass near 1418.7 |
| Amino acid count | 15 | single chain, no disulfide bonds |
| Solubility | freely soluble in water | also dissolves in saline and phosphate buffer |
| Common synonyms | pentadecapeptide BPC, BPC 157 | fragment notation varies by source |
BPC-157 is a synthetic peptide composed of fifteen amino acid residues, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its name derives from body protection compound, a term used for a protein fraction identified in human gastric juice. Researchers in Zagreb first reported the pentadecapeptide in the early 1990s and described it as a stable fragment of that larger protein. The compound is also catalogued as PL 14736 and, in some commercial contexts, as bepecin. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Most published work on BPC-157 consists of preclinical studies, including rodent models of tissue injury, gastrointestinal lesions, and vascular or tendon damage, together with in vitro cell assays. Reviews frequently note that the mechanisms proposed in these papers remain incompletely characterised and that findings have not been confirmed in large randomised human trials. The compound is widely sold as a research chemical rather than a licensed medicine, and labels commonly carry a statement that it is not for human use. Whether any of the reported animal effects translate to humans is an open question rather than an established result.
Terminology in the literature is not fully standardised. Papers and product listings use BPC-157, BPC 157, and the longer phrase stable gastric pentadecapeptide BPC 157 interchangeably, and synonyms such as bepecin or PL 14736 appear in older or company-linked publications. Purity claims and reported masses can also differ between sources because peptide preparations may include counterions, residual solvents, or bound water. This variability complicates direct comparison of results across studies and makes the exact identity and grade of a given sample worth verifying. Discussions of the compound should therefore specify the source, salt form, and stated purity where those are known.
Once dissolved, the material is considerably less stable than the dry solid. Aqueous solutions are usually kept cold and used within a short window, and neutral or mildly acidic buffers are preferred over strongly alkaline conditions. Freeze-thaw cycles promote aggregation and loss of material to container surfaces, so dividing a batch into single-use aliquots is standard. Adsorption to plastic and glass can lower the measured concentration, meaning solution strength may need rechecking before an experiment.
Identity and purity are established with complementary methods rather than one test. Reverse-phase high-performance liquid chromatography separates the main peak from deletion sequences and oxidized variants, and its area percentage is the usual purity figure. Mass spectrometry confirms the expected molecular mass and can flag truncations or modifications that chromatography alone might miss. Amino acid analysis and peptide mapping add sequence-level confirmation, while residual counter-ion and water content are measured separately.
A freeze-dried sample is generally the most stable form and is commonly held at minus twenty degrees Celsius or lower for long-term keeping, with brief transfers at room temperature. The solid is hygroscopic, so vials are warmed to ambient temperature before opening to prevent condensation from degrading the contents. Light exposure and repeated temperature cycling are both avoided in routine handling. Storage over a desiccant is a common laboratory practice that limits moisture uptake during repeated access.
Proposed mechanisms include interaction with the nitric oxide system, modulation of growth factor signaling, and effects on blood vessel formation. None of these has been established as the primary mode of action, and some proposed pathways rest on indirect measurements. Whether the reported effects depend on a specific receptor has not been determined. Stability in gastric acid, unusual for a peptide of this size, is also reported in animal work, but the reason for it is not firmly established.
Published studies on BPC-157 are dominated by animal models. Commonly used endpoints include healing of surgically induced lesions in the stomach, tendon-to-bone attachment after transection, and recovery from experimentally induced vascular or intestinal damage. Many of these reports come from a small number of research groups, and the peptide is often described as acting across a wide range of tissue types. That breadth is itself a point of discussion, since one molecule influencing many unrelated systems is unusual.
Human data are far more limited than animal data. A small number of clinical reports exist, generally with few participants and without the randomization or blinding expected in later-phase trials. No large, independently replicated human trial has appeared in the indexed peer-reviewed literature. Statements about effects in people therefore rest on extrapolation from animal work rather than on direct evidence, and the strength of that extrapolation remains an open question rather than a settled matter.
Outside laboratory supply channels, the peptide is sold as a research chemical, a category that carries no requirement to demonstrate purity, identity, or freedom from contamination. Because it is not an approved medicine, products labeled BPC-157 sit in a regulatory gap in many countries, and actual content may differ from the label. Sports organizations list it among prohibited substances, so its presence in an athlete's sample can produce a doping finding regardless of how the material was obtained.
BPC-157 is a synthetic peptide of fifteen amino acids, written as GEPPPGKPADDAGLV, whose sequence matches part of a larger protein identified in human gastric juice. That parent protein was described in stomach-secretion research, and the fifteen-residue fragment was named body protection compound, which gives the peptide its common label. Material used in experiments is produced by solid-phase peptide synthesis rather than extracted from tissue. The reported molecular weight is about 1419 daltons, and the chain contains several proline residues, a feature that appears in discussions of its resistance to enzymatic breakdown.
Harris also expressed support for student debt relief, and said she supported raising the minimum wage. In response to the housing crisis in the United States, Harris said she would increase home construction to reduce housing costs, arguing that it negatively impacts the economy and hurts working-class families. Harris proposed directing $40 billion to construction companies to build starter homes, and promised to send $25,000 in down-payment assistance to every first time home buyer. Harris said she would urge Congress to enforce fair housing laws and pass a bill to bar property owners from using services that "coordinate" rents through the passage of the Preventing the Algorithmic Facilitation of Rental Housing Cartels Act, and also call on Congress to pass the Stop Predatory Investing Act by removing tax benefits to Wall Street firms that buy up large numbers of single-family homes. Trump proposed further individual and corporate tax cuts beyond the 2017 Tax Cuts and Jobs Act. Trump argued that keeping taxes low for the wealthy increases job creation, and that these policies coupled with a crackdown in illegal immigration and reduction in inflation would help the middle class. Trump said he would reduce regulation of business through the creation of an efficiency commission led by Musk, along with reducing environmental regulation. By October 2024, Musk was Trump's second-largest individual campaign donor.
=== EC 1.14.19 With oxidation of a pair of donors resulting in the reduction of O2 to two molecules of water === EC 1.14.19.1: stearoyl-CoA 9-desaturase EC 1.14.19.2: stearoyl-[acyl-carrier-protein] 9-desaturase EC 1.14.19.3: linoleoyl-CoA desaturase EC 1.14.19.4: acyl-lipid (11-3)-desaturase EC 1.14.19.5: acyl-CoA 11-(Z)-desaturase EC 1.14.19.6: acyl-CoA (9+3)-desaturase EC 1.14.19.7: Now EC 1.11.1.23, (S)-2-hydroxypropylphosphonic acid epoxidase EC 1.14.19.8: pentalenolactone synthase EC 1.14.19.9: tryptophan 7-halogenase EC 1.14.19.10: icosanoyl-CoA 5-desaturase EC 1.14.19.11: acyl-[acyl-carrier-protein] 4-desaturase EC 1.14.19.12: acyl-lipid ω-(9-4) desaturase EC 1.14.19.13: acyl-CoA 15-desaturase EC 1.14.19.14: linoleoyl-lipid Δ9 conjugase EC 1.14.19.15: (11Z)-hexadec-11-enoyl-CoA conjugase EC 1.14.19.16: linoleoyl-lipid Δ12 conjugase (11E,13Z-forming) EC 1.14.19.17: sphingolipid 4-desaturase EC 1.14.19.18: sphingolipid 8-(E)-desaturase EC 1.14.19.19: sphingolipid 10-desaturase EC 1.14.19.20: Δ7-sterol 5(6)-desaturase EC 1.14.19.21: cholesterol 7-desaturase EC 1.14.19.22: acyl-lipid ω-6 desaturase (cytochrome b5) EC 1.14.19.23: acyl-lipid (n+3)-(Z)-desaturase (ferredoxin) EC 1.14.19.24: acyl-CoA 11-(E)-desaturase EC 1.14.19.25: acyl-lipid ω-3 desaturase (cytochrome b5) EC 1.14.19.26: acyl-[acyl-carrier-protein] 6-desaturase EC 1.14.19.27: sn-2 palmitoyl-lipid 9-desaturase EC 1.14.19.28: sn-1 stearoyl-lipid 9-desaturase EC 1.14.19.29: sphingolipid 8-(E/Z)-desaturase EC 1.14.19.30: acyl-lipid (8-3)-desaturase EC 1.14.19.31: acyl-lipid (7-3)-desaturase EC 1.14.19.32: palmitoyl-CoA 14-(E/Z)-desaturase EC 1.14.19.33: Δ12 acyl-lipid conjugase (11E,13E-forming) EC 1.14.19.34: acyl-lipid (9+3)-(E)-desaturase EC 1.14.19.35: sn-2 acyl-lipid ω-3 desaturase (ferredoxin) EC 1.14.19.36: sn-1 acyl-lipid ω-3 desaturase (ferredoxin) EC 1.14.19.37: acyl-CoA 5-desaturase EC 1.14.19.38: acyl-lipid Δ6-acetylenase EC 1.14.19.39: acyl-lipid Δ12-acetylenase EC 1.14.19.40: hex-5-enoyl-[acyl-carrier protein] acetylenase EC 1.14.19.41: sterol 22-desaturase EC 1.14.19.42: palmitoyl-[glycerolipid] 7-desaturase EC 1.14.19.43: palmitoyl-[glycerolipid] 3-(E)-desaturase EC 1.14.19.44: acyl-CoA (8-3)-desaturase EC 1.14.19.45: sn-1 oleoyl-lipid 12-desaturase EC 1.14.19.46: sn-1 linoleoyl-lipid 6-desaturase EC 1.14.19.47: acyl-lipid (9-3)-desaturase EC 1.14.19.48: tert-amyl alcohol desaturase EC 1.14.19.49: tetracycline 7-halogenase EC 1.14.19.50: noroxomaritidine synthase EC 1.14.19.51: (S)-corytuberine synthase EC 1.14.19.52: camalexin synthase EC 1.14.19.53: all-trans-retinol 3,4-desaturase EC 1.14.19.54: 1,2-dehydroreticuline synthase EC 1.14.19.55: 4-hydroxybenzoate brominase (decarboxylating) EC 1.14.19.56: 1H-pyrrole-2-carbonyl-[peptidyl-carrier protein] chlorinase EC 1.14.19.57: 1H-pyrrole-2-carbonyl-[peptidyl-carrier protein] brominase EC 1.14.19.58: tryptophan 5-halogenase EC 1.14.19.59: tryptophan 6-halogenase EC 1.14.19.60: 7-chloro-L-tryptophan 6-halogenase EC 1.14.19.61: dihydrorhizobitoxine desaturase EC 1.14.19.62: secologanin synthase EC 1.14.19.63: pseudobaptigenin synthase EC 1.14.19.64: (S)-stylopine synthase EC 1.14.19.65: (S)-cheilanthifoline synthase EC 1.14.19.66: berbamunine synthase EC 1.14.19.67: salutaridine synthase EC 1.14.19.68: (S)-canadine synthase EC 1.14.19.69: biflaviolin synthase EC 1.14.19.70: mycocyclosin synthase EC 1.14.19.71: fumitremorgin C synthase EC 1.14.19.72: (–)-pluviatolide synthase EC 1.14.19.73: (S)-nandinine synthase EC 1.14.19.74: (+)-piperitol/(+)-sesamin synthase EC 1.14.19.75: very-long-chain acyl-lipid ω-9 desaturase EC 1.14.19.76: flavone synthase II EC 1.14.19.77: plasmanylethanolamine desaturase EC 1.14.19.78: decanoyl-[acyl-carrier protein] acetylenase
== Clinical use == Tylosin has been used to treat a variety of different diseases throughout the world. Differing formulations and licensing conditions mean it may not be a recognized method of treatment for certain conditions in certain countries. In general, tylosin is licensed for the treatment of infections caused by organisms susceptible to the drug, but it has also been used as a treatment of colitis in small animals, as a growth promotant in food-producing animals, and as a way of reducing epiphora (tear staining) around the eyes of white-faced dogs. In these cases, the result is positive only when using the tylosin in the form of tartrate, a chelating porphyrin. No marketing authority exists for the use of other tylosin forms as a tear-stain remover, thus it is not legal to use it for such purposes; the exception is as a prescription-only medicine of last resort by veterinarians under the cascading rule (UK) or the extra-label use rule (US). Examples of bacterial infections that could potentially be treated with tylosin include respiratory infections, metritis, and acute mastitis in cattle; mastitis in sheep and goats; enteritis, pneumonia, erysipelas, and infectious arthritis in swine; and soft-tissue infections in small animals. While tylosin may be one appropriate therapeutic choice in theory for the conditions listed above, many other antibiotics may be preferable for treating a specific infection, and tylosin will not be the first choice. It is also used as a growth promoter for a variety of terrestrial and aquatic animals grown for human consumption.
== Mechanism of antimicrobial activity == The general rule of the mechanism triggering cathelicidin action, like that of other antimicrobial peptides, involves the disintegration (damaging and puncturing) of cell membranes of organisms toward which the peptide is active. Cathelicidins rapidly destroy the lipoprotein membranes of microbes enveloped in phagosomes after fusion with lysosomes in macrophages. Therefore, LL-37 can inhibit the formation of bacterial biofilms.
Sources: en.wikipedia.org
== Mechanism == The synthetase first binds ATP and the corresponding amino acid (or its precursor) to form an aminoacyl-adenylate, releasing inorganic pyrophosphate (PPi). The adenylate-aaRS complex then binds the appropriate tRNA molecule's D arm, and the amino acid is transferred from the aa-AMP to either the 2'- or the 3'-OH of the last tRNA nucleotide (A76) at the 3'-end. The mechanism can be summarized in the following reaction series:
In July 2009, there were a series of coordinated denial of service attacks against major government, news media, and financial websites in South Korea and the United States. While many thought the attack was directed by North Korea, one researcher traced the attacks to the United Kingdom. Security researcher Chris Kubecka presented evidence multiple European Union and United Kingdom companies unwittingly helped attack South Korea due to a W32.Dozer infections, malware used in part of the attack. Some of the companies used in the attack were partially owned by several governments, further complicating cyber attribution. In July 2011, the South Korean company SK Communications was hacked, resulting in the theft of the personal details (including names, phone numbers, home and email addresses and resident registration numbers) of up to 35 million people. A trojaned software update was used to gain access to the SK Communications network. Links exist between this hack and other malicious activity and it is believed to be part of a broader, concerted hacking effort. With ongoing tensions on the Korean Peninsula, South Korea's defense ministry stated that South Korea was going to improve cyber-defense strategies in hopes of preparing itself from possible cyber attacks. In March 2013, South Korea's major banks – Shinhan Bank, Woori Bank and NongHyup Bank – as well as many broadcasting stations – KBS, YTN and MBC – were hacked and more than 30,000 computers were affected; it is one of the biggest attacks South Korea has faced in years.
Bacterial plasmids are circular sections of DNA that naturally replicate in bacteria. Plasmids are capable of holding inserts up to approximately 20 kbp in length. These types of constructs typically contain a gene offering antibiotic-resistance, an origin of replication, regulatory elements such as Lac inhibitors, a polylinker, and a protein tag which facilitates protein purification. Bacteriophage Vectors are viruses that can infect bacteria and replicate their own DNA. Artificial chromosomes are commonly used in genome project studies due to their ability to hold inserts up to 350 kbp. These vectors are derived from the F plasmid, taking advantage of the high stability and conjugational ability introduced by the F factor. Fosmids are a hybrid between bacterial F plasmids and λ phage cloning techniques. Inserts are pre-packaged into phage particles, then inserted into the host cell with the ability to hold ~45 kbp. They are typically used to generate a DNA library due to their increased stability.
Sources: en.wikipedia.org
The sequence corresponds to a fragment of a protein found in human gastric juice, so related sequences are natural. The isolated fifteen-amino-acid peptide supplied for research is produced synthetically. Whether the free fragment circulates naturally in humans has not been settled.
In most jurisdictions it is not an approved medicine and is handled as a research material. Import and sale rules differ by country, and some regulators have placed it in categories that restrict human use. Status can change, so current local rules apply.
Rodent models dominate, particularly rats with induced gastric lesions, tendon injury, or vascular disruption. These designs allow controlled comparison but differ anatomically and metabolically from humans. Results from such models are commonly cited as preliminary.
Human data are limited. Most evidence comes from animal experiments and from small or uncontrolled reports. The absence of large trials means clinical effects and safety are not firmly established.